Please refer attached pdf.

Date: July 29, 2026 To, To, Corporate Relationship Department Listing Compliance Department BSE Limited National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers, Exchange Plaza, 5th Floor, Plot No. C/2, 25th Floor, Dalal Street, G-Block, Bandra Kurla Complex, Bandra (E), Mumbai – 400001, India Mumbai – 400051, India Scrip Code: 532305 Symbol: INDSWFTLAB Subject: Intimation under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, Corrigendum to the Notice of 01/2026-27 Extra-Ordinary General Meeting (“EGM Notice”) dated July 10, 2026. Dear Sir/Ma’am, In continuation to our intimation dated July 14, 2026, we are hereby submitting the Corrigendum to the Notice of the Extra Ordinary General Meeting (“EGM”) scheduled to be held on Wednesday, August 05, 2026, at 11:30 A.M. (IST) through Video Conferencing (“VC”)/Other Audio-Visual Means (“OAVM”). A Corrigendum has been issued to inform the Shareholders of the Company regarding the changes in Item No. 1 of the EGM Notice. The same is enclosed herewith. All other particulars and details mentioned in the EGM Notice shall remain unchanged. The Corrigendum shall be read in conjunction with the EGM Notice dated July 10, 2026, together with the Explanatory Statement. This Corrigendum is also available on the Company’s website viz. www.indswiftgroup.com , and on the website of BSE Limited and National Stock Exchange of India Limited at www.bseindia.com and www.nseindia.com respectively. All Capitalized words and expressions used but not defined herein shall have the same meaning as assigned to them in the EGM Notice. You are requested to take the same on your record. Thanking You, For Ind-Swift Laboratories Limited Pardeep Verma VP - Corporate Affairs & Company Secretary IND-SWIFT LABOPRATORIES LIMITED CIN: L24232CH1995PLC015553 Registered Office: SCO:850, Shivalik Enclave, NAC, Manimajra, Chandigarh – 160101, India Email: investor@indswiftlabs.com Website: www.indswiftgroup.com Corrigendum to the Notice of the Extra Ordinary General Meeting (“EGM Notice”) dated July 10, 2026, for the members of Ind-Swift Laboratories Limited (“the Company”) to be held on Wednesday, August 05, 2026, at 11:30 A.M. IST through Video Conferencing (“VC”)/ Other Audio - Visual Means (“OAVM”). Dear Members, This is in continuation to the Notice of Extra Ordinary General Meeting (“EGM Notice”) dated July 10, 2026, convening Extra Ordinary General Meeting of the members of Ind-Swift Laboratories Limited (“the Company”) to be held on Wednesday, August 05, 2026, for seeking approval for matters contained in the said Notice. The Notice of the EGM was dispatched to the shareholders of the Company in due compliance with the provisions of the Companies Act, 2013, and rules made thereunder, read with circulars issued by Ministry of Corporate Affairs and Securities and Exchange Board of India. In this regard we would like to mention that with regard to Item No. 01 of the same, the Company had filed application with the BSE Limited (“BSE”) and National Stock Exchange of India Limited (“NSE”) (hereinafter collectively referred to as “Stock Exchanges”), for seeking In-principle approval in relation to the proposed Preferential Issue of 70,00,000 Fully Convertible Warrants to entity belonging to ‘Promoter & Promoter Group’, for which the approval of the shareholders is being sought. Thereafter, the Company received certain observations from BSE and NSE. This Corrigendum is being issued pursuant to the observations of both the stock exchanges. The Company through this communication wishes to bring to the notice of the Shareholders, the following changes in Item No. 01 of the said EGM Notice and Explanatory Statement: Changes to the Explanatory Statement A. Point No. I titled ‘Objects of the Preferential Issue’ of the Explanatory Statement to the EGM Notice shall be substituted and read as under: The Company is a research-led pharmaceutical company wherein we manufacture a wide range of formulations, including tablets, capsules, ointments, liquids and dry syrups at our facilities located at Jawaharpur, Derabassi (PB); Parwanoo (H.P.) and Jammu (J&K), including a 100% Export- Oriented Global Business Unit (GBU) at Derabassi (PB). In order to expand its current facilities and support future product development initiatives, the Company intends to utilize the proceeds raised through the issue of Fully Convertible Warrants (“Issue Proceeds”) towards following objects: 1. Expansion of Business: a. Expansion of Existing Manufacturing Facility and Setting up of Warehouse: As mentioned above, company has its existing manufacturing facility located at Jawaharpur, Derabassi (PB) and Jammu (J&K) wherein it is proposing to expand CORRIGENDUM TO THE NOTICE OF EGM manufacturing capacity of these facilities along with setting up of a new Warehouse at Jawaharpur, Derabassi (PB), adjoining our existing manufacturing facility. b. Research & Development (‘R&D’): Being a pharmaceutical Company, it has to continuously engage in R&D activities, thus, a portion of the Issue proceeds is proposed to be utilised in the R&D of new pharmaceutical formulations and purchase of pilot scale formulation equipment and analytical equipment for R&D of these formulations. c. Technology Upgradation: The Company is proposing to utilise part of proceeds towards (i) Implementation and customization of SAP systems and (ii) Development and deployment of Building Management Systems at the Plants of the Company. d. Investment in our subsidiary: The Company is proposing to make investment in one of its subsidiaries namely ISLL Middle East LLC-FZ, Dubai. Our subsidiary would utilise the said infused amount for its Marketing and Business Development. 2. To meet the Working Capital Requirements of the Company. 3. General Corporate Purposes subject to such utilisation not exceeding 25% of the total consideration. (Hereinafter collectively referred to as “Objects”) Utilization of Proceeds Given that the funds to be received against Warrants, the Issue Proceeds shall be received by the Company in tranches depending upon the subscription and conversion of Warrants. Since the funds to be received against Warrant conversion will be in stages and the quantum of funds required at different points of time may vary, the broad range of intended utilization of the Issue Proceeds towards the aforesaid Objects of the Issue has been set out here in below: S. No. Particulars Estimated Tentative timeline for utilization of the utilization of issue Issue Proceeds proceeds from the date (Rs. in Crore) * of receipt of funds 1. Expansion of Business a. Expansion of Existing Manufacturing 41.40 December 31, 2029 Facility and Setting up of a new Warehouse b. Research & Development (‘R&D’) 2.00 c. Technology Upgradation 1.50 d. Investment in subsidiary 5.00 2. To meet the Working Capital Requirements 53.00 December 31, 2028 of the Company. 3. General Corporate Purposes 34.30 December 31, 2028 Total 137.20 (*) considering 100% conversion of Warrants into Equity Shares within the stipulated time. Given that the Preferential Issue is for Warrants, the entire Issue Proceeds from the Proposed Allottee will be received by the Company within 18 months from the date of allotment of Warrants CORRIGENDUM TO THE NOTICE OF EGM in terms of Chapter V of SEBI (ICDR) Regulations, and as estimated by the Company’s management, the entire Issue Proceeds would be utilized for all the aforementioned objects, in phases, as per the Company’s business requirements and availability of Issue Proceeds. Schedule of Implementation and Deployment of Funds Our Company, in accordance with the policies formulated and in accordance with the applicable laws and guidelines and description as given in this Notice, will have the flexibility to deploy the proceeds. Pending utilization of the proceeds for the purposes described above, our Company intends to deposit the Gro [Showing first 8,000 characters — download PDF for full document]